Kenneth S. Suslick (born 1952) is the Marvin T. Schmidt Professor of Chemistry Emeritus at the University of Illinois at Urbana–Champaign.

He was the lead consultant for Molecular Biosystems Inc. and part of the team that commercialized the first echo contrast agent for medical sonography, Albunex™, which became Optison™ by GE Healthcare.

In addition, he was the founding consultant for VivoRx Pharmaceuticals and helped invent and commercialize Abraxane™, albumin microspheres with a paclitaxel core, which is the predominant current delivery system for taxol chemotherapy for breast cancer; VivoRx became Abraxis Bioscience, which was acquired by Celgene for $2.9 billion.

[11] The Suslick Research Group at the University of Illinois at Urbana–Champaign is multi-disciplinary and has worked on three major research areas: (1) the chemical and physical effects of ultrasound (which includes nano-materials synthesis and sonoluminescence); (2) the mechanochemistry of inorganic solids (including shock wave energy dissipation by MOFs, i.e., metal-organic framework solids); and (3) chemical sensing, molecular recognition, and artificial olfaction, which is a spinoff of earlier work on the bioinorganic and materials chemistry of metalloporphyrins.

Of particular interest is the development of the optoelectronic nose, i.e., colorimetric sensor arrays for the detection of VOCs, toxic industrial chemicals, explosives, as well as diverse QA/QC applications for foods and beverages.